Moderna (MRNA) Stock Forecast & Price Target

$69.86

-2.13 (-2.96%)

(As of 09/18/2024 ET)

Moderna - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold
Based on 19 Analyst Ratings

Based on 19 Wall Street analysts who have issued ratings for Moderna in the last 12 months, the stock has a consensus rating of "Hold." Out of the 19 analysts, 2 have given a sell rating, 13 have given a hold rating, and 4 have given a buy rating for MRNA.

Consensus Price Target

$100.44
43.77% Upside

High Forecast	$179.00
Average Forecast	$100.44
Low Forecast	$48.00

According to the 19 analysts' twelve-month price targets for Moderna, the average price target is $100.44. The highest price target for MRNA is $179.00, while the lowest price target for MRNA is $48.00. The average price target represents a forecasted upside of 43.77% from the current price of $69.86.

Type	Current Forecast 9/20/23 to 9/19/24	1 Month Ago 8/21/23 to 8/20/24	3 Months Ago 6/22/23 to 6/21/24	1 Year Ago 9/20/22 to 9/20/23
Consensus Rating	Hold	Hold	Hold	Hold
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	4 Buy rating(s)	7 Buy rating(s)	6 Buy rating(s)	6 Buy rating(s)
Hold	13 Hold rating(s)	8 Hold rating(s)	9 Hold rating(s)	9 Hold rating(s)
Sell	2 Sell rating(s)	1 Sell rating(s)	2 Sell rating(s)	3 Sell rating(s)
Consensus Price Target	$100.44	$124.07	$129.02	$155.52
Forecasted Upside	43.77% Upside	21.72% Upside	19.54% Upside	12.79% Upside

$25,000 into $109,616 in two months? (Ad)

Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…

Go here to watch the most recent trading workshop video at no charge.

MRNA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MRNA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Moderna Stock vs. The Competition

Type	Moderna	Medical Companies	S&P 500
Consensus Rating Score	2.11	2.77	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	43.77% Upside	1,009.46% Upside	7.94% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/17/2024	Leerink Partners 1 of 5 stars		Lower Target	Underperform ➝ Underperform	$60.00 ➝ $48.00	-34.09%
9/16/2024	The Goldman Sachs Group 2 of 5 stars		Lower Target	Buy ➝ Buy	$178.00 ➝ $139.00	+101.19%
9/16/2024	Barclays 3 of 5 stars		Lower Target	Overweight ➝ Overweight	$155.00 ➝ $125.00	+80.06%
9/13/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$130.00 ➝ $110.00	+62.87%
9/13/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$70.00 ➝ $60.00	-9.92%
9/13/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	L. Issi Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Sector Perform ➝ Sector Perform	$90.00 ➝ $75.00	+12.60%
Trump Warns Gov. Can Confiscate Your Money. CBDC's give Gov. absolute (Ad) Donald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it. This means you must act NOW before it's too late.
9/13/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Hold
9/13/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$157.00 ➝ $115.00	+65.04%
9/13/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$120.00 ➝ $65.00	-6.72%
9/13/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Neutral ➝ Underweight	$88.00 ➝ $70.00	+0.46%
9/13/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
8/28/2024	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Y. Liu Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Sell ➝ Hold
8/28/2024	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Reduce ➝ Hold	$82.00	+3.82%
8/7/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Sell ➝ Hold	$85.00 ➝ $80.00	-2.79%
6/27/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Market Perform
6/27/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Kasimov Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	In-Line ➝ In-Line	$120.00 ➝ $120.00	-2.00%
5/7/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$143.00 ➝ $151.00	+26.77%
5/3/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$91.00 ➝ $106.00	-15.20%
9/13/2023	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$160.00 ➝ $140.00	+26.96%
8/4/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$128.00 ➝ $123.00	+13.37%
6/26/2023	51job Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Upgrade
4/25/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral
2/24/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Market Perform ➝ Underperform	$111.00 ➝ $93.00	-36.98%
1/25/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Market Perform	$130.00 ➝ $150.00	-23.76%
1/18/2023	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Y. Livshits Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral	$191.00 ➝ $208.00	+4.17%
10/20/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$165.00 ➝ $145.00	+18.07%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 05:25 AM ET.

MRNA Forecast - Frequently Asked Questions

What is Moderna's forecast for 2024?: According to the research reports of 19 Wall Street equities research analysts, the average twelve-month stock price forecast for Moderna is $100.44, with a high forecast of $179.00 and a low forecast of $48.00.
Should I buy or sell Moderna stock right now?: 19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Moderna in the last twelve months. There are currently 2 sell ratings, 13 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" MRNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRNA, but not buy additional shares or sell existing shares.
Does Moderna's stock price have much upside?: According to analysts, Moderna's stock has a predicted upside of 19.78% based on their 12-month stock forecasts.
Has Moderna been upgraded or downgraded by Wall Street analysts recently?: Over the previous 90 days, Moderna's stock had 4 downgrades and 3 upgrades by analysts.
What analysts cover Moderna?: Moderna has been rated by research analysts at Bank of America, Barclays, Deutsche Bank Aktiengesellschaft, Evercore ISI, Hsbc Global Res, HSBC, Jefferies Financial Group, JPMorgan Chase & Co., Leerink Partners, Needham & Company LLC, Oppenheimer, Piper Sandler, Royal Bank of Canada, TD Cowen, The Goldman Sachs Group, and William Blair in the past 90 days.
Do Wall Street analysts like Moderna more than its competitors?: Analysts like Moderna less than other "medical" companies. The consensus rating for Moderna is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how MRNA compares to other companies.